Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Up 6.8% – Time to Buy?

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) were up 6.8% during trading on Wednesday. The company traded as high as $16.50 and last traded at $16.3910. 12,451 shares changed hands during trading, an increase of 84% from the average session volume of 6,777 shares. The stock had previously closed at $15.35.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on AAPG shares. BTIG Research reissued a “buy” rating and issued a $48.00 price objective on shares of Ascentage Pharma Group International in a research report on Friday, August 21st. Raymond James Financial reaffirmed a “buy” rating on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. Finally, B. Riley Financial started coverage on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. They issued a “buy” rating and a $45.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company’s stock. According to MarketBeat, Ascentage Pharma Group International presently has a consensus rating of “Buy” and a consensus target price of $46.43.

Ascentage Pharma Group International Stock Up 6.8%

The company has a fifty day moving average of $17.21 and a two-hundred day moving average of $19.76. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.18 and a current ratio of 1.22.

Ascentage Pharma Group International (NASDAQ:AAPG) last issued its quarterly earnings data on Wednesday, August 19th. The company reported ($0.65) EPS for the quarter. The business had revenue of $22.24 million during the quarter. As a group, equities research analysts forecast that Ascentage Pharma Group International – Unsponsored ADR will post -2.42 earnings per share for the current year.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a biopharmaceutical company focused on discovering and developing therapies that target apoptosis, the natural process of programmed cell death. Its research is directed primarily toward cancer and other serious diseases in which abnormal cell survival contributes to disease progression.

The company’s pipeline includes small-molecule drug candidates designed to inhibit proteins involved in apoptosis regulation, including BCL-2, MDM2 and inhibitor-of-apoptosis proteins.